Symbols / GALT Stock $2.35 +5.38% Galectin Therapeutics Inc.

Healthcare • Biotechnology • United States • NCM
GALT (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Joel Lewis CPA
Exch · Country NCM · United States
Market Cap 154.69M
Enterprise Value 276.91M
Income -30.97M
Sales —
FCF (ttm) -20.90M
Book/sh -1.97
Cash/sh 0.27
Employees 9
Insider 10d —
IPO Sep 04, 2002
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1.40
PEG -36.15
P/S —
P/B -1.19
P/C —
EV/EBITDA —
EV/Sales —
Quick Ratio 2.21
Current Ratio 2.42
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -0.48
EPS next Y -1.68
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-31
Earnings (prior) 2026-03-31
ROA -67.81%
ROE —
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 65.83M
Shs Float 47.16M
Insider Own 29.10%
Instit Own 18.51%
Short Float 17.61%
Short Ratio 21.93
Short Interest 7.39M
52W High 7.13
vs 52W High -67.04%
52W Low 1.21
vs 52W Low 94.21%
Beta 0.45
Impl. Vol. 25.00%
Rel Volume 0.73
Avg Volume 327.75K
Volume 238.85K
Target (mean) $11.00
Tgt Median $11.00
Tgt Low $11.00
Tgt High $11.00
# Analysts 1
Recom None
Prev Close $2.23
Price $2.35
Change 5.38%
About

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$11.00
Mean price target
2. Current target
$2.35
Latest analyst target
3. DCF / Fair value
$-5.72
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.35
Low
$11.00
High
$11.00
Mean
$11.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-12-17 main HC Wainwright & Co. Buy → Buy $11
2025-08-14 reit HC Wainwright & Co. Buy → Buy $6
2025-04-02 reit HC Wainwright & Co. Neutral → Neutral —
2024-12-27 down HC Wainwright & Co. Buy → Neutral —
2024-11-15 reit HC Wainwright & Co. Buy → Buy $11
2024-08-16 reit HC Wainwright & Co. Buy → Buy $11
2024-04-09 reit HC Wainwright & Co. Buy → Buy $11
2024-04-01 reit HC Wainwright & Co. Buy → Buy $11
2023-08-15 reit HC Wainwright & Co. Buy → Buy $11
2023-05-17 reit HC Wainwright & Co. Buy → Buy $11
2023-03-03 reit HC Wainwright & Co. — → Buy $11
2022-05-17 main HC Wainwright & Co. — → Buy $11
2021-04-16 main HC Wainwright & Co. — → Buy $14
2020-08-13 main HC Wainwright & Co. — → Buy $12
2020-04-03 main B. Riley Securities — → Buy $4
2020-03-17 main HC Wainwright & Co. — → Buy $9
2019-02-13 init B. Riley Securities — → Buy $11
2017-10-19 init Roth Capital — → Buy $8
2017-10-06 init Seaport Global — → Buy $5
2017-03-30 up HC Wainwright & Co. Neutral → Buy $4
News
RSS: Latest GALT news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-06 ELDRED KARY N. Director — 300 $2.70 $810
2026-01-16 UIHLEIN RICHARD E Director and Beneficial Owner of more than 10% of a Class of Security — 13,158 $3.04 $40,000
2026-01-06 CALLICUTT JACK W Chief Financial Officer — 60,000 $3.67 $233,388
2026-01-06 LEWIS JOEL Chief Executive Officer — 84,000 $3.58 $321,134
2026-01-06 JAMIL KHURRAM Officer — 60,000 $3.65 $232,402
2026-01-02 CALLICUTT JACK W Chief Financial Officer — 60,000 — —
2026-01-02 LEWIS JOEL Chief Executive Officer — 84,000 — —
2026-01-02 JAMIL KHURRAM Officer — 60,000 — —
2025-12-31 JAMIL KHURRAM Officer — 8,125 $1.23 $9,994
2025-12-31 JAMIL KHURRAM Officer — 8,125 $4.07 $33,089
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
20.09
-52.67%
42.43
+11.45%
38.07
-0.73%
38.35
Research And Development
14.29
-60.93%
36.57
+13.82%
32.13
+1.24%
31.74
Selling General And Administration
5.79
-1.14%
5.86
-1.35%
5.94
-10.17%
6.62
General And Administrative Expense
5.79
-1.14%
5.86
-1.35%
5.94
-10.17%
6.62
Other Gand A
5.79
-1.14%
5.86
-1.35%
5.94
-10.17%
6.62
Total Expenses
20.09
-52.67%
42.43
+11.45%
38.07
-0.73%
38.35
Operating Income
-20.09
+52.67%
-42.43
-11.45%
-38.07
+0.73%
-38.35
Total Operating Income As Reported
-20.09
+52.67%
-42.43
-11.45%
-38.07
+0.73%
-38.35
EBITDA
-23.45
+43.44%
-41.47
-8.44%
-38.24
-1.41%
-37.71
Normalized EBITDA
-19.91
+52.67%
-42.06
-11.24%
-37.81
+1.20%
-38.27
Reconciled Depreciation
0.05
+43.24%
0.04
+12.12%
0.03
+3.13%
0.03
EBIT
-23.51
+43.37%
-41.51
-8.45%
-38.27
-1.41%
-37.74
Total Unusual Items
-3.55
-703.40%
0.59
+236.11%
-0.43
-177.56%
0.56
Total Unusual Items Excluding Goodwill
-3.55
-703.40%
0.59
+236.11%
-0.43
-177.56%
0.56
Net Income
-30.84
+34.46%
-47.05
-14.56%
-41.07
-5.91%
-38.78
Pretax Income
-30.84
+34.46%
-47.05
-14.56%
-41.07
-5.91%
-38.78
Net Non Operating Interest Income Expense
-7.20
-38.47%
-5.20
-103.04%
-2.56
-161.16%
-0.98
Interest Expense Non Operating
7.33
+32.29%
5.54
+98.42%
2.79
+170.28%
1.03
Net Interest Income
-7.20
-38.47%
-5.20
-103.04%
-2.56
-161.16%
-0.98
Interest Expense
7.33
+32.29%
5.54
+98.42%
2.79
+170.28%
1.03
Interest Income Non Operating
0.13
-62.72%
0.34
+46.96%
0.23
+342.31%
0.05
Interest Income
0.13
-62.72%
0.34
+46.96%
0.23
+342.31%
0.05
Other Income Expense
-3.55
-703.40%
0.59
+236.11%
-0.43
-177.56%
0.56
Gain On Sale Of Security
-3.55
-703.40%
0.59
+236.11%
-0.43
-177.56%
0.56
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-30.84
+34.46%
-47.05
-14.56%
-41.07
-5.91%
-38.78
Net Income From Continuing Operation Net Minority Interest
-30.84
+34.46%
-47.05
-14.56%
-41.07
-5.91%
-38.78
Net Income From Continuing And Discontinued Operation
-30.84
+34.46%
-47.05
-14.56%
-41.07
-5.91%
-38.78
Net Income Continuous Operations
-30.84
+34.46%
-47.05
-14.56%
-41.07
-5.91%
-38.78
Normalized Income
-27.29
+42.71%
-47.63
-17.23%
-40.63
-3.31%
-39.33
Net Income Common Stockholders
-30.97
+34.38%
-47.20
-5.35%
-44.80
-15.26%
-38.87
Otherunder Preferred Stock Dividend
—
0.00
-100.00%
3.62
0.00
Diluted EPS
-0.48
+36.84%
-0.76
-2.70%
-0.74
-13.85%
-0.65
Basic EPS
-0.48
+36.84%
-0.76
-2.70%
-0.74
-13.85%
-0.65
Basic Average Shares
63.90
+2.56%
62.31
+3.57%
60.16
+1.29%
59.39
Diluted Average Shares
63.90
+2.56%
62.31
+3.57%
60.16
+1.29%
59.39
Diluted NI Availto Com Stockholders
-30.97
+34.38%
-47.20
-5.35%
-44.80
-15.26%
-38.87
Preferred Stock Dividends
0.14
-9.80%
0.15
+27.50%
0.12
+23.71%
0.10
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
19.53
+11.64%
17.50
-37.96%
28.20
+32.49%
21.29
Current Assets
19.44
+12.66%
17.25
-37.74%
27.71
+34.83%
20.55
Cash Cash Equivalents And Short Term Investments
17.72
+17.20%
15.12
-41.08%
25.66
+38.02%
18.59
Cash And Cash Equivalents
17.72
+17.20%
15.12
-41.08%
25.66
+38.02%
18.59
Prepaid Assets
—
—
—
—
Other Current Assets
1.72
-19.51%
2.13
+4.00%
2.05
+4.59%
1.96
Total Non Current Assets
0.10
-60.49%
0.24
-50.41%
0.49
-33.15%
0.73
Net PPE
0.00
0.00
0.00
0.00
Gross PPE
0.07
+0.00%
0.07
+0.00%
0.07
+0.00%
0.07
Accumulated Depreciation
-0.07
+0.00%
-0.07
+0.00%
-0.07
+0.00%
-0.07
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.07
+0.00%
0.07
+0.00%
0.07
+0.00%
0.07
Other Properties
—
—
—
0.73
Leases
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Other Non Current Assets
0.10
-60.49%
0.24
-50.41%
0.49
-33.15%
0.73
Total Liabilities Net Minority Interest
145.73
+20.87%
120.56
+36.32%
88.44
+65.38%
53.48
Current Liabilities
8.03
-77.32%
35.41
+125.88%
15.68
+20.47%
13.01
Payables And Accrued Expenses
6.95
-43.85%
12.38
-14.62%
14.50
+20.85%
12.00
Payables
3.31
-42.16%
5.72
-11.93%
6.49
+64.24%
3.95
Accounts Payable
3.25
-42.63%
5.66
-12.05%
6.43
+65.32%
3.89
Dividends Payable
0.06
+0.00%
0.06
+0.00%
0.06
-1.56%
0.06
Current Accrued Expenses
3.64
-45.30%
6.66
-16.80%
8.01
-0.47%
8.04
Pensionand Other Post Retirement Benefit Plans Current
1.06
-30.66%
1.52
+34.90%
1.13
+16.03%
0.97
Current Debt And Capital Lease Obligation
0.02
-99.90%
21.14
+45847.83%
0.05
+15.00%
0.04
Current Debt
—
21.12
—
—
Other Current Borrowings
—
21.12
—
—
Current Capital Lease Obligation
0.02
+15.79%
0.02
-58.70%
0.05
+15.00%
0.04
Other Current Liabilities
—
0.37
—
—
Total Non Current Liabilities Net Minority Interest
137.70
+61.70%
85.16
+17.03%
72.77
+79.81%
40.47
Long Term Debt And Capital Lease Obligation
133.74
+57.13%
85.11
+18.63%
71.74
+80.13%
39.83
Long Term Debt
133.74
+57.13%
85.11
+18.63%
71.74
+80.13%
39.83
Other Non Current Liabilities
—
—
0.02
-69.70%
0.07
Stockholders Equity
-126.19
-22.44%
-103.07
-71.10%
-60.24
-87.12%
-32.19
Common Stock Equity
-128.41
-21.95%
-105.29
-68.57%
-62.46
-81.44%
-34.43
Capital Stock
2.28
-0.31%
2.29
+0.04%
2.28
-0.35%
2.29
Common Stock
0.07
+4.84%
0.06
+1.64%
0.06
+3.39%
0.06
Preferred Stock
2.21
-0.45%
2.22
+0.00%
2.22
-0.45%
2.23
Share Issued
65.20
+3.24%
63.16
+2.11%
61.85
+4.08%
59.43
Ordinary Shares Number
65.20
+3.24%
63.16
+2.11%
61.85
+4.08%
59.43
Additional Paid In Capital
304.07
+2.65%
296.22
+1.50%
291.85
+6.09%
275.08
Retained Earnings
-432.55
-7.71%
-401.57
-13.32%
-354.37
-14.47%
-309.57
Total Equity Gross Minority Interest
-126.19
-22.44%
-103.07
-71.10%
-60.24
-87.12%
-32.19
Total Capitalization
7.54
+141.98%
-17.96
-256.18%
11.50
+50.64%
7.63
Working Capital
11.41
+162.82%
-18.16
-250.88%
12.03
+59.60%
7.54
Invested Capital
5.33
+470.95%
0.93
-89.94%
9.28
+71.76%
5.40
Total Debt
133.76
+25.89%
106.25
+48.00%
71.79
+80.06%
39.87
Net Debt
116.02
+27.34%
91.11
+97.71%
46.08
+116.99%
21.24
Capital Lease Obligations
0.02
+15.79%
0.02
-58.70%
0.05
+15.00%
0.04
Net Tangible Assets
-126.19
-22.44%
-103.07
-71.10%
-60.24
-87.12%
-32.19
Tangible Book Value
-128.41
-21.95%
-105.29
-68.57%
-62.46
-81.44%
-34.43
Derivative Product Liabilities
3.96
+8329.79%
0.05
-95.32%
1.00
+75.22%
0.57
Preferred Stock Equity
2.21
-0.45%
2.22
+0.00%
2.22
-0.45%
2.23
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-23.88
+42.84%
-41.77
-26.70%
-32.97
-6.15%
-31.06
Cash Flow From Continuing Operating Activities
-23.88
+42.84%
-41.77
-26.70%
-32.97
-6.15%
-31.06
Net Income From Continuing Operations
-30.84
+34.46%
-47.05
-14.56%
-41.07
-5.91%
-38.78
Depreciation Amortization Depletion
0.05
+43.24%
0.04
+12.12%
0.03
+3.13%
0.03
Depreciation
0.05
+43.24%
0.04
+12.12%
0.03
+3.13%
0.03
Depreciation And Amortization
0.05
+43.24%
0.04
+12.12%
0.03
+3.13%
0.03
Other Non Cash Items
1.09
-0.55%
1.10
+57.82%
0.70
+70.00%
0.41
Stock Based Compensation
1.66
-32.20%
2.45
+8.23%
2.26
-21.14%
2.87
Operating Gains Losses
3.55
+703.06%
-0.59
-236.11%
0.43
+177.56%
-0.56
Gain Loss On Investment Securities
3.55
+703.06%
-0.59
-236.11%
0.43
+177.56%
-0.56
Change In Working Capital
0.61
-73.34%
2.28
-51.18%
4.68
-5.84%
4.97
Change In Prepaid Assets
0.42
+607.32%
-0.08
+8.89%
-0.09
-189.11%
0.10
Change In Payables And Accrued Expense
0.19
-91.84%
2.37
-50.38%
4.77
-2.03%
4.87
Change In Accrued Expense
6.24
+40.43%
4.44
+111.73%
2.10
+236.60%
0.62
Change In Payable
-6.04
-191.32%
-2.07
-177.65%
2.67
-37.06%
4.24
Change In Account Payable
-6.04
-191.32%
-2.07
-177.65%
2.67
-37.06%
4.24
Investing Cash Flow
0.00
0.00
0.00
0.00
Financing Cash Flow
26.48
-15.22%
31.23
-22.00%
40.03
+300.33%
10.00
Cash Flow From Continuing Financing Activities
26.48
-15.22%
31.23
-22.00%
40.03
+300.33%
10.00
Net Issuance Payments Of Debt
21.00
-30.00%
30.00
+0.00%
30.00
+200.00%
10.00
Issuance Of Debt
21.00
-30.00%
30.00
+0.00%
30.00
+200.00%
10.00
Long Term Debt Issuance
21.00
-30.00%
30.00
+0.00%
30.00
+200.00%
10.00
Net Long Term Debt Issuance
21.00
-30.00%
30.00
+0.00%
30.00
+200.00%
10.00
Net Common Stock Issuance
3.23
0.00
—
0.00
Proceeds From Stock Option Exercised
2.24
+82.56%
1.23
-87.77%
10.03
0.00
Changes In Cash
2.60
+124.67%
-10.54
-249.12%
7.07
+133.57%
-21.06
Beginning Cash Position
15.12
-41.08%
25.66
+38.02%
18.59
-53.11%
39.65
End Cash Position
17.72
+17.20%
15.12
-41.08%
25.66
+38.02%
18.59
Free Cash Flow
-23.88
+42.84%
-41.77
-26.70%
-32.97
-6.15%
-31.06
Change In Interest Payable
6.24
+40.43%
4.44
+111.73%
2.10
+236.60%
0.62
Common Stock Issuance
3.23
0.00
—
0.00
Issuance Of Capital Stock
3.23
0.00
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category